Fractyl Health is a biotechnology company that provides curative therapies for metabolic diseases.
Fractyl Health develops innovative medical device solutions for the treatment of chronic diseases. The growing product pipeline leverages our minimally invasive procedural therapy, Revita DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. They envision a world with better solutions to chronic diseases through the use of less invasive, device-based therapies that will lessen the burden on patients, physicians, and payers.Fractyl Health aims to bring curative therapies to the large populations of patients with metabolic disease.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 15, 2022 | Series F | — | 1 | — | — | Detail |
Nov 30, 2017 | Series D | $44M | 2 | — | — | Detail |
Nov 19, 2015 | Series C | $57M | 1 | — | — | Detail |
Sep 4, 2014 | Series B | $19.76M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
General Catalyst | — | Series F |
iDo Fund | — | Series D |